Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Interactions of 6-methoxy-2-naphtyl acetic acid (6mna) with human serum proteins: possibility of site ii binding inhibitor in clinical

  • At: 2004 FIP Congress in New Orleans (USA)
  • Type: Poster
  • By: TOKUNAGA, JIn (Kyusyu University of Health and Welfare, Second Department of Clinical Pharmacy, Nobeoka, Japan)
  • Co-author(s): Takamura (Kyusyu University of Health and Welfare, NOBEOKA, Japan)
    Chosa (Miyazaki Medical College, Japan)
    Motoya (Kyusyu University of Health and Welfare, NOBEOKA, Japan)
    Fujita (Miyazaki Medical College, Japan)
    Okumura (Miyazaki Medical College, Japan)
    Yamasaki (Miyazaki Medical College, Japan)
    Ogata (Kyusyu University of Health and Welfare, NOBEOKA, Japan)
    Hidaka (Miyazaki Medical College, Japan)
    Kodama (Miyazaki Medical College, Japan)
    Kuroki (Chiyoda Hospital, Japan)
    Kai (Chiyoda Hospital, Japan)
    Chiyotanda (Chiyoda Hospital, Japan)
    Kawai (Kanazawa University, Japan)
    Arimori (Miyazaki Medical College, Japan)
  • Abstract:

    Purpose: Nabumetone (Relifen®), which has a high selectivity of cyclooxygenase II, is one of non-steroidal anti-inflammatory drugs (NSAIDs) commercially available. Nabumetone is a prodrug of 6-methoxy-2-naphtyl acetic acid (6MNA). Its biological half-time is long and its therapeutic concentration is high. If 6MNA binds to serum proteins strongly, ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses